|
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
|
|
|
|
rs121909219
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs751409106
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
|
rs80358683
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF(V599E) mutations were unique to PTCs, and not found in any of the other types of differentiated follicular neoplasms arising from the same cell type (0 of 46).
|
12670889 |
2003 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V599E) mutations were unique to PTCs, and not found in any of the other types of differentiated follicular neoplasms arising from the same cell type (0 of 46).
|
12670889 |
2003 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
These resu</span>lts suggest that BRAF(V599E) mutation is frequent in the etiopathogenesis of PTC.
|
12881714 |
2003 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These resu</span>lts suggest that BRAF(V599E) mutation is frequent in the etiopathogenesis of PTC.
|
12881714 |
2003 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.
|
12970315 |
2003 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.
|
12970315 |
2003 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF(V599E) was also detected in 6 of 11 cases of the oncocytic variant of PTC that displayed a papillary or mixed follicular-papillary growth pattern and in none of the four oncocytic PTCs with a follicular growth pattern.
|
14743508 |
2004 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V599E) was also detected in 6 of 11 cases of the oncocytic variant of PTC that displayed a papillary or mixed follicular-papillary growth pattern and in none of the four oncocytic PTCs with a follicular growth pattern.
|
14743508 |
2004 |
|
rs121913364
|
|
|
0.070 |
GeneticVariation |
BEFREE |
A distinct mutation in BRAF (codon K600E) was detected in three cases of the follicular variant of PTC.
|
14743508 |
2004 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The V599E mutation is highly prevalent in PTC with a papillary or mixed papillary follicular growth pattern, and the K600E mutation is apparently restricted to the follicular variant of PTC.
|
15095090 |
2004 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The V599E mutation is highly prevalent in PTC with a papillary or mixed papillary follicular growth pattern, and the K600E mutation is apparently restricted to the follicular variant of PTC.
|
15095090 |
2004 |
|
rs121913364
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The V599E mutation is highly prevalent in PTC with a papillary or mixed papillary follicular growth pattern, and the K600E mutation is apparently restricted to the follicular variant of PTC.
|
15095090 |
2004 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
These data clearly confirm that BRAF(V599E) is the more common genetic alteration found to date in adult sporadic PTCs, that it is unique for this thyroid cancer histotype, and that it might drive the development of PTCs of the classic papillary subtype.
|
15126572 |
2004 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data clearly confirm that BRAF(V599E) is the more common genetic alteration found to date in adult sporadic PTCs, that it is unique for this thyroid cancer histotype, and that it might drive the development of PTCs of the classic papillary subtype.
|
15126572 |
2004 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In conclusion, the present study on the first Italian series of thyroid cancers shows a frequency of 38.3% of BRAF(V599E) in the classical variant of PTC, confirming the key role of this mutation in promoting tumourigenesis.
|
15272920 |
2004 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the present study on the first Italian series of thyroid cancers shows a frequency of 38.3% of BRAF(V599E) in the classical variant of PTC, confirming the key role of this mutation in promoting tumourigenesis.
|
15272920 |
2004 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The analysis of exons 11 and 15 of BRAF gene revealed the T1796A (V599E) mutation in 32% of cases, and this alteration is significantly associated with PTC tall cell variant.
|
15273715 |
2004 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The analysis of exons 11 and 15 of BRAF gene revealed the T1796A (V599E) mutation in 32% of cases, and this alteration is significantly associated with PTC tall cell variant.
|
15273715 |
2004 |
|
rs75076352
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We tested on thyroid follicular cells the transforming activity of RET(C634S), RET(K603Q), another mutant identified in a kindred with both PTC and MTC, RET(C634R) a commonly isolated allele in MEN2A, RET(M918T) responsible for MEN2B and also identified in kindreds with both PTC and MTC, and RET/PTC1 the rearranged oncogene that characterizes bona fide PTC in patients without MTC.
|
15277225 |
2004 |
|
rs377767394
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We tested on thyroid follicular cells the transforming activity of RET(C634S), RET(K603Q), another mutant identified in a kindred with both PTC and MTC, RET(C634R) a commonly isolated allele in MEN2A, RET(M918T) responsible for MEN2B and also identified in kindreds with both PTC and MTC, and RET/PTC1 the rearranged oncogene that characterizes bona fide PTC in patients without MTC.
|
15277225 |
2004 |
|
rs74799832
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We tested on thyroid follicular cells the transforming activity of RET(C634S), RET(K603Q), another mutant identified in a kindred with both PTC and MTC, RET(C634R) a commonly isolated allele in MEN2A, RET(M918T) responsible for MEN2B and also identified in kindreds with both PTC and MTC, and RET/PTC1 the rearranged oncogene that characterizes bona fide PTC in patients without MTC.
|
15277225 |
2004 |